22 results on '"Coupé, Veerle M. H."'
Search Results
2. KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer
- Author
-
Uil, Sjoerd H., Coupé, Veerle M. H., Bril, Herman, Meijer, Gerrit A., Fijneman, Remond J. A., and Stockmann, Hein B. A. C.
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and cost-utility of the eHealth self-management application 'Oncokompas', helping partners of patients with incurable cancer to identify their unmet supportive care needs and to take actions to meet their needs: a study protocol of a randomized controlled trial
- Author
-
Schuit, Anouk S., Holtmaat, Karen, Hooghiemstra, Nienke, Jansen, Femke, Lissenberg-Witte, Birgit I., Coupé, Veerle M. H., and Verdonck-de Leeuw, Irma M.
- Published
- 2020
- Full Text
- View/download PDF
4. Prevalence of adjustment disorder among cancer patients, and the reach, effectiveness, cost-utility and budget impact of tailored psychological treatment: study protocol of a randomized controlled trial
- Author
-
van Beek, Florie E., Wijnhoven, Lonneke M. A., Jansen, Femke, Custers, José A. E., Aukema, Eline J., Coupé, Veerle M. H., Cuijpers, Pim, van der Lee, Marije L., Lissenberg-Witte, Birgit I., Wijnen, Ben, Prins, Judith B., and Verdonck-de Leeuw, Irma M.
- Published
- 2019
- Full Text
- View/download PDF
5. Efficacy and cost-utility of the eHealth application ‘Oncokompas’, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial
- Author
-
Schuit, Anouk S., Holtmaat, Karen, Hooghiemstra, Nienke, Jansen, Femke, Lissenberg-Witte, Birgit I., Coupé, Veerle M. H., van Linde, Myra E., Becker-Commissaris, Annemarie, Reijneveld, Jaap C., Zijlstra, Josée M., Sommeijer, Dirkje W., Eerenstein, Simone E. J., and Verdonck-de Leeuw, Irma M.
- Published
- 2019
- Full Text
- View/download PDF
6. Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study
- Author
-
den Uil, Sjoerd H., van den Broek, Evert, Coupé, Veerle M. H., Vellinga, Thomas T., Delis-van Diemen, Pien M., Bril, Herman, Belt, Eric J. Th., Kranenburg, Onno, Stockmann, Hein B. A. C., Belien, Jeroen A. M., Meijer, Gerrit A., and Fijneman, Remond J. A.
- Published
- 2019
- Full Text
- View/download PDF
7. Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer
- Author
-
Engelhardt, Ellen G., Révész, Dóra, Tamminga, Hans J., Punt, Cornelis J. A., Koopman, Miriam, Onwuteaka-Philipsen, Bregje D., Steyerberg, Ewout W., de Vet, Henrica C. W., and Coupé, Veerle M. H.
- Published
- 2018
- Full Text
- View/download PDF
8. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) – a phase III single-blind prospective randomized controlled trial
- Author
-
Puijk, Robbert S., Ruarus, Alette H., Vroomen, Laurien G. P. H., van Tilborg, Aukje A. J. M., Scheffer, Hester J., Nielsen, Karin, de Jong, Marcus C., de Vries, Jan J. J., Zonderhuis, Babs M., Eker, Hasan H., Kazemier, Geert, Verheul, Henk, van der Meijs, Bram B., van Dam, Laura, Sorgedrager, Natasha, Coupé, Veerle M. H., van den Tol, Petrousjka M. P., Meijerink, Martijn R., and COLLISION Trial Group
- Published
- 2018
- Full Text
- View/download PDF
9. Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening
- Author
-
Bronzwaer, Maxime E. S., Greuter, Marjolein J. E., Bleijenberg, Arne G. C., IJspeert, Joep E. G., Dekker, Evelien, and Coupé, Veerle M. H.
- Published
- 2018
- Full Text
- View/download PDF
10. A progressive three-state model to estimate time to cancer: a likelihood-based approach.
- Author
-
Akwiwu, Eddymurphy U., Klausch, Thomas, Jodal, Henriette C., Carvalho, Beatriz, Løberg, Magnus, Kalager, Mette, Berkhof, Johannes, H. Coupé, Veerle M., and Coupé, Veerle M H
- Abstract
Background: To optimize colorectal cancer (CRC) screening and surveillance, information regarding the time-dependent risk of advanced adenomas (AA) to develop into CRC is crucial. However, since AA are removed after diagnosis, the time from AA to CRC cannot be observed in an ethically acceptable manner. We propose a statistical method to indirectly infer this time in a progressive three-state disease model using surveillance data.Methods: Sixteen models were specified, with and without covariates. Parameters of the parametric time-to-event distributions from the adenoma-free state (AF) to AA and from AA to CRC were estimated simultaneously, by maximizing the likelihood function. Model performance was assessed via simulation. The methodology was applied to a random sample of 878 individuals from a Norwegian adenoma cohort.Results: Estimates of the parameters of the time distributions are consistent and the 95% confidence intervals (CIs) have good coverage. For the Norwegian sample (AF: 78%, AA: 20%, CRC: 2%), a Weibull model for both transition times was selected as the final model based on information criteria. The mean time among those who have made the transition to CRC since AA onset within 50 years was estimated to be 4.80 years (95% CI: 0; 7.61). The 5-year and 10-year cumulative incidence of CRC from AA was 13.8% (95% CI: 7.8%;23.8%) and 15.4% (95% CI: 8.2%;34.0%), respectively.Conclusions: The time-dependent risk from AA to CRC is crucial to explain differences in the outcomes of microsimulation models used for the optimization of CRC prevention. Our method allows for improving models by the inclusion of data-driven time distributions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care: study protocol for a randomised controlled trial.
- Author
-
van der Hout, Anja, van Uden-Kraan, Cornelia F., Witte, Birgit I., Coupé, Veerle M. H., Jansen, Femke, Leemans, C. René, Cuijpers, Pim, van de Poll-Franse, Lonneke V., and Verdonck-de Leeuw, Irma M.
- Subjects
CANCER patient care ,SELF-management (Psychology) ,RANDOMIZED controlled trials ,COLON cancer diagnosis ,BREAST cancer diagnosis - Abstract
Background: Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.Methods/design: Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included. In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group. The primary outcome measure is patient activation. Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life. Furthermore, cost-utility outcomes will be assessed. Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial. Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up.Discussion: In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas. These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas.Trial Registration: Netherlands Trial Register identifier: NTR5774 . Registered on 8 March 2016. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI.
- Author
-
Greuter, Marjolein J. E., Schouten, Charlotte S., Castelijns, Jonas A., de Graaf, Pim, Comans, Emile F. I., Hoekstra, Otto S., de Bree, Remco, Coupé, Veerle M. H., Greuter, Marjolein Je, Comans, Emile Fi, and Coupé, Veerle Mh
- Subjects
CHEMORADIOTHERAPY ,PHARYNGEAL cancer ,MAGNETIC resonance imaging of cancer ,COST effectiveness ,ANESTHETICS ,PHARMACODYNAMICS ,DIAGNOSIS ,PATIENTS ,CANCER treatment ,DEOXY sugars ,DIAGNOSTIC imaging ,LONGITUDINAL method ,MAGNETIC resonance imaging ,PROGNOSIS ,RADIOPHARMACEUTICALS ,TUMOR classification ,OROPHARYNGEAL cancer ,ECONOMICS - Abstract
Background: Considerable variation exists in diagnostic tests used for local response evaluation after chemoradiation in patients with advanced oropharyngeal cancer. The yield of invasive examination under general anesthesia (EUA) with biopsies in all patients is low and it may induce substantial morbidity. We explored four response evaluation strategies to detect local residual disease in terms of diagnostic accuracy and cost-effectiveness.Methods: We built a decision-analytic model using trial data of forty-six patients and scientific literature. We estimated for four strategies the proportion of correct diagnoses, costs concerning diagnostic instruments and the proportion of unnecessary EUA indications. Besides a reference strategy, i.e. EUA for all patients, we considered three imaging strategies consisting of 18FDG-PET-CT, diffusion-weighted MRI (DW-MRI), or both 18FDG-PET-CT and DW-MRI followed by EUA after a positive test. The impact of uncertainty was assessed in sensitivity analyses.Results: The EUA strategy led to 96% correct diagnoses. Expected costs were €468 per patient whereas 89% of EUA indications were unnecessary. The DW-MRI strategy was the least costly strategy, but also led to the lowest proportion of correct diagnoses, i.e. 93%. The PET-CT strategy and combined imaging strategy were dominated by the EUA strategy due to respectively a smaller or equal proportion of correct diagnoses, at higher costs. However, the combination of PET-CT and DW-MRI had the highest sensitivity. All imaging strategies considerably reduced (unnecessary) EUA indications and its associated burden compared to the EUA strategy.Conclusions: Because the combined PET-CT and DW-MRI strategy costs only an additional €927 per patient, it is preferred over immediate EUA since it reaches the same diagnostic accuracy in detecting local residual disease while leading to substantially less unnecessary EUA indications. However, if healthcare resources are limited, DW-MRI is the strategy of choice because of lower costs while still providing a large reduction in unnecessary EUA indications. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.
- Author
-
van Lanschot, Meta C. J., Carvalho, Beatriz, Coupé, Veerle M. H., van Engeland, Manon, Dekker, Evelien, and Meijer, Gerrit A.
- Subjects
COLON cancer ,COLONOSCOPY ,FECES examination ,POLYPECTOMY ,COHORT analysis ,DNA analysis ,ADENOMA ,COLON tumors ,COMPARATIVE studies ,EXPERIMENTAL design ,FECES ,IMMUNOCHEMISTRY ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RECTUM tumors ,RESEARCH ,EVALUATION research ,CROSS-sectional method ,EARLY detection of cancer ,DIAGNOSIS ,ECONOMICS - Abstract
Background: As in many other European countries, a nationwide screening program for colorectal cancer (CRC) has recently been introduced in the Netherlands. As a side effect, such a screening program will inherently yield an increase in the demand for surveillance after removal of polyps/adenomas or CRC. Although these patients are at increased risk of metachronous colorectal neoplasia, solid evidence on CRC-related mortality reduction as a result of colonoscopy-based surveillance programs is lacking. Furthermore, colonoscopy-based surveillance leads to high patient burden, high logistic demands and high costs. Therefore, new surveillance strategies are needed. The aim of the present study, named Molecular stool testing for Colorectal CAncer Surveillance (MOCCAS), is to determine the performance characteristics of two established non-invasive tests, i.e., the multitarget stool DNA test Cologuard® and the faecal immunochemical test (FIT) in the detection of CRC and advanced adenomas as an alternative for colonoscopy surveillance.Methods: In this observational cross-sectional cohort study, subjects aged 50 to 75 years will be approached to collect (whole-) stool samples for molecular testing and a FIT prior to their scheduled surveillance colonoscopy. The results of the tests will allow calculation of test sensitivities and specificities in the context of surveillance. This will provide the required input for the Dutch ASCCA model (Adenoma and Serrated pathway to Colorectal CAncer) to simulate surveillance strategies differing in frequency and duration. The model will allow predictions of lifetime health effects and costs. Multiple centres in the Netherlands will participate in the study that aims to include 4,000 individuals.Discussion: The outcome of this study will inform on the (cost-) effectiveness of stool based molecular testing as an alternative for colonoscopy in the rapidly expanding surveillance population.Trial Registration: ClinicalTrials.gov ( https://clinicaltrials.gov/ ): NCT02715141 . Retrospectively registered 17 February 2016. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Resilience of a FIT screening programme against screening fatigue: a modelling study.
- Author
-
Greuter, Marjolein J. E., Berkhof, Johannes, Canfell, Karen, Lew, Jie-Bin, Dekker, Evelien, and Coupé, Veerle M. H.
- Subjects
COLON cancer ,FATIGUE (Physiology) ,MORTALITY ,HUMAN behavior ,MEDICAL screening - Abstract
Background: Repeated participation is important in faecal immunochemical testing (FIT) screening for colorectal cancer (CRC). However, a large number of screening invitations over time may lead to screening fatigue and consequently, decreased participation rates. We evaluated the impact of screening fatigue on overall screening programme effectiveness. Methods: Using the ASCCA model, we simulated the Dutch CRC screening programme consisting of biennial FIT screening in individuals aged 55-75. We studied the resilience of the programme against heterogeneity in screening attendance and decrease in participation rate due to screening fatigue. Outcomes were reductions in CRC incidence and mortality compared to no screening. Results: Assuming a homogenous 63 % participation, i.e., each round each individual was equally likely to attend screening, 30 years of screening reduced CRC incidence and mortality by 39 and 53 %, respectively, compared to no screening. When assuming clustered participation, i.e., three subgroups of individuals with a high (95 %), moderate (65 %) and low (5 %) participation rate, screening was less effective; reductions were 33 % for CRC incidence and 43 % for CRC mortality. Screening fatigue considerably reduced screening effectiveness; if individuals refrained from screening after three negative screens, model-predicted incidence reductions decreased to 25 and 18 % under homogenous and clustered participation, respectively. Figures were 34 and 25 % for mortality reduction. Conclusions: Screening will substantially decrease CRC incidence and mortality. However, screening effectiveness can be seriously compromised if screening fatigue occurs. This warrants careful monitoring of individual screening behaviour and consideration of targeted invitation systems in individuals who have (repeatedly) missed screening rounds. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Effectiveness and cost-utility of a guided self-help exercise program for patients treated with total laryngectomy: protocol of a multi-center randomized controlled trial.
- Author
-
Jansen, Femke, Cnossen, Ingrid C., Eerenstein, Simone E. J., Coupé, Veerle M. H., Witte, Birgit I., van Uden-Kraan, Cornelia F., Doornaert, Patricia, Braunius, Weibel W., De Bree, Remco, Hardillo, José A. U., Honings, Jimmie, Halmos, György B., Leemans, C. René, Leeuw, Irma M. Verdonck-de, and Verdonck-de Leeuw, Irma M
- Subjects
LARYNGECTOMY ,PHYSICAL training & conditioning ,SHOULDER exercises ,LARYNGECTOMEES ,RANDOMIZED controlled trials ,EXERCISE therapy ,COMPARATIVE studies ,COST effectiveness ,DEGLUTITION disorders ,EXPERIMENTAL design ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PATIENT education ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH ,HEALTH self-care ,SPEECH disorders ,EVALUATION research ,TREATMENT effectiveness ,ECONOMICS - Abstract
Background: Total laryngectomy with or without adjuvant (chemo)radiation often induces speech, swallowing and neck and shoulder problems. Speech, swallowing and shoulder exercises may prevent or diminish these problems. The aim of the present paper is to describe the study, which is designed to investigate the effectiveness and cost-utility of a guided self-help exercise program built into the application "In Tune without Cords" among patients treated with total laryngectomy.Methods/design: Patients, up to 5 years earlier treated with total laryngectomy with or without (chemo)radiation will be recruited for participation in this study. Patients willing to participate will be randomized to the intervention or control group (1:1). Patients in the intervention group will be provided access to a guided self-help exercise program and a self-care education program built into the application "In Tune without Cords". Patients in the control group will only be provided access to the self-care education program. The primary outcome is the difference in swallowing quality (SWAL-QOL) between the intervention and control group. Secondary outcome measures address speech problems (SHI), shoulder disability (SDQ), quality of life (EORTC QLQ-C30, QLQ-H&N35 and EQ-5D), direct and indirect costs (adjusted iMCQ and iPCQ measures) and self-management (PAM). Patients will be asked to complete these outcome measures at baseline, immediately after the intervention or control period (i.e. at 3 months follow-up) and at 6 months follow-up.Discussion: This randomized controlled trial will provide knowledge on the effectiveness of a guided self-help exercise program for patients treated with total laryngectomy. In addition, information on the value for money of such an exercise program will be provided. If this guided self-help program is (cost)effective for patients treated with total laryngectomy, the next step will be to implement this exercise program in current clinical practice.Trial Registration: NTR5255 Protocol version 4 date September 2015. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?
- Author
-
van Turenhout, Sietze T., Oort, Frank A., van der Hulst, René W. M., Visscher, Arjen P., sive Droste, Jochim S. Terhaar, Scholten, Pieter, Bouman, Anneke A., Meijer, Gerrit A., Mulder, Chris J. J., van Rossum, Leo G. M., and Coupé, Veerle M. H.
- Subjects
COLON cancer diagnosis ,EARLY detection of cancer ,SEX factors in disease ,IMMUNOCHEMISTRY ,HEALTH outcome assessment ,COLONOSCOPY ,COMPARATIVE studies - Abstract
Background: Faecal immunochemical tests (FITs) are commonly used in colorectal cancer (CRC) screening. Diagnostic accuracy of FIT differs between males and females. This so far unexplained difference could result in a dissimilarity in screening outcome between both sexes. The aim of this study is to compare sensitivity and specificity of a FIT between males and females, and study potential explanatory variables Methods: In this cross-sectional study, data were prospectively collected. 3,022 subjects performed a FIT prior to complete colonoscopy. Sensitivity, specificity, and ROC curves were compared for both sexes. Potential explanatory variables of the relation between sensitivity and sex were explored. Results: At all cut-off values, FIT sensitivity for CRC was higher (range 13-23%) and specificity was lower (range 2-4%) in males compared to females. At 75 ng/ml, sensitivity for CRC was 93% in males compared to 71% in females (p = 0.03), and specificity was 90% in males compared to 93% in females (p = <0.05). For advanced adenomas, males had a slightly higher sensitivity and lower specificity (not significant). At 75 ng/ml, sensitivity for advanced adenomas was 33% in males compared to 29% in females (p = 0.46), and specificity was 93% in males compared to 95% in females (p = 0.22). ROC curves were similar for both sexes, and equal combinations of sensitivity and specificity could be achieved by adjusting the cut-off values. For CRC, the difference in sensitivity could not be explained by age or location of the tumour. Conclusions: FIT has a higher sensitivity and a lower specificity for CRC in males than in females. Equal test characteristics can be achieved by allowing separate cut-off values for both sexes. Location and age do not explain the observed differences in sensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. Study protocol: Cost effectiveness of two strategies to implement the NVOG guidelines on hypertension in pregnancy: An innovative strategy including a computerised decision support system compared to a common strategy of professional audit and feedback, a randomized controlled trial.
- Author
-
Luitjes, Susanne H. E., Wouters, Maurice G. A. J., Franx, Arie, Scheepers, Hubertina C. J., Coupé, Veerle M. H., Wollersheim, Huub, Steegers, Eric A. P., Heringa, Martijn P., Hermens, Rosella P. M. G., van Tulder, Maurits W., Luitjes, Susanne He, Wouters, Maurice Gaj, Scheepers, Hubertina Cj, Coupé, Veerle Mh, Steegers, Eric Ap, and Hermens, Rosella Pmg
- Subjects
HYPERTENSION ,PREGNANCY ,COST effectiveness ,RANDOMIZED controlled trials - Abstract
Background: Hypertensive disease in pregnancy remains the leading cause of maternal mortality in the Netherlands. Seventeen percent of the clinical pregnancies are complicated by hypertension and 2% by preeclampsia. The Dutch Society of Obstetrics and Gynaecology (NVOG) has developed evidence-based guidelines on the management of hypertension in pregnancy and chronic hypertension. Previous studies showed a low adherence rate to other NVOG guidelines and a large variation in usual care in the different hospitals. An explanation is that the NVOG has no general strategy of practical implementation and evaluation of its guidelines. The development of an effective and cost effective implementation strategy to improve adherence to the guidelines on hypertension in pregnancy is needed.Methods/design: The objective of this study is to assess the cost effectiveness of an innovative implementation strategy of the NVOG guidelines on hypertension including a computerised decision support system (BOS) compared to a common strategy of professional audit and feedback. A cluster randomised controlled trial with an economic evaluation alongside will be performed. Both pregnant women who develop severe hypertension or pre-eclampsia and professionals involved in the care for these women will participate. The main outcome measures are a combined rate of major maternal complications and process indicators extracted from the guidelines. A total of 472 patients will be included in both groups. For analysis, descriptive as well as regression techniques will be used. A cost effectiveness and cost utility analysis will be performed according to the intention-to-treat principle and from a societal perspective. Cost effectiveness ratios will be calculated using bootstrapping techniques. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
18. Does delay in diagnosing colorectal cancer insymptomatic patients affect tumor stage andsurvival? A population-based observational study.
- Author
-
Droste, Jochim S. Terhaar sive, Oort, Frank A., van der Hulst, René W. M., Coupé, Veerle M. H., Craanen, Mike E., Meijer, Gerrit A., Morsink, Linde M., Visser, Otto, van Wanrooij, Roy L. J., and Mulder, Chris J. J.
- Subjects
COLON cancer diagnosis ,CONFIDENCE intervals ,QUESTIONNAIRES ,MULTIVARIATE analysis - Abstract
Background: Diagnosing colorectal cancer (CRC) at an early stage improves survival. To what extent any delay affects outcome once patients are symptomatic is still unclear. Our objectives were to evaluate the association between diagnostic delay and survival in symptomatic patients with early stage CRC and late stage CRC. Methods: Prospective population-based observational study evaluating daily clinical practice in Northern Holland. Diagnostic delay was determined through questionnaire-interviews. Dukes' stage was classified into two groups: early stage (Dukes A or B) and late stage (Dukes C or D) cancer. Patients were followed up for 3.5 years after diagnosis. Results: In total, 272 patients were available for analysis. Early stage CRC was present in 136 patients while 136 patients had late stage CRC. The mean total diagnostic delay (SE) was 31 (1.5) weeks in all CRC patients. No significant difference was observed in the mean total diagnostic delay in early versus late stage CRC (p = 0.27). In early stage CRC, no difference in survival was observed between patients with total diagnostic delay shorter and longer than the median (Kaplan-Meier, log-rank p = 0.93). In late stage CRC, patients with a diagnostic delay shorter than the median had a shorter survival than patients with a diagnostic delay longer than the median (log-rank p = 0.01). In the multivariate Cox regression model with survival as dependent variable and median delay, age, open access endoscopy, number and type of symptoms as independent variables, the odd's ratio for survival in patients with long delay (>median) versus short delay (≤median) was 1.8 (95% confidence interval (CI) 1.1 to 3.0; p = 0.01). Tumor-site was not associated with patient survival. When separating late stage CRC in Dukes C and Dukes D tumors, a shorter delay was associated with a shorter survival in Dukes D tumors only and not in Dukes C tumors. Conclusion: In symptomatic CRC patients, a longer diagnostic and therapeutic delay in routine clinical practice was not associated with an adverse effect on survival. The time to CRC diagnosis and initiation of treatment did not differ between early stage and late stage colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Cost-effectiveness of the SEN-concept: Specialized Emergency Nurses (SEN) treating ankle/foot injuries.
- Author
-
Derksen, Robert J., Coupé, Veerle M. H., van Tulder, Maurits W., Veenings, Bart, and Bakker, Fred C.
- Subjects
- *
COST effectiveness , *NURSES , *ANKLE injury treatment , *FOOT injuries , *WOUND care , *EMERGENCY nursing , *THERAPEUTICS - Abstract
Background: Emergency Departments (EDs) are confronted with progressive overcrowding. As a consequence, the workload for ED physicians increases and waiting times go up with the risk of unnecessary complications and patient dissatisfaction. To cope with these problems, Specialized Emergency Nurses (SENs), regular ED-nurses receiving a short, injury-specific course, were trained to assess and treat minor injuries according to a specific protocol. Methods: An economic evaluation was conducted alongside a randomized controlled trial comparing House Officers (HOs) and SENs in their assessment of ankle and foot injuries. Cost prices were established for all parts of healthcare utilization involved. Total costs of health care utilization were computed per patient in both groups. Cost-effectiveness was investigated by comparing the difference in total cost between groups with the difference in sensitivity and specificity between groups in diagnosing fractures and severe sprains. Finally, cost-effectiveness ratios were calculated and presented on a cost-effectiveness plane. Results: No significant differences were seen between treatment groups for any of the health care resources assessed. However, the waiting times for both first assessment by a treatment officer and time spent waiting between hearing the diagnosis and final treatment were significantly longer in the HO group. There was no statistically significant difference in costs between groups. The total costs were € 186 (SD € 623) for patients in the SEN group and € 153 (SD € 529) for patients in the HO group. The difference in total costs was € 33 (95% CI: - € 84 to € 155). The incremental cost-effectiveness ratio was € 27 for a reduction of one missed diagnosis and € 18 for a reduction of one false negative. Conclusion: Considering the benefits of the SEN-concept in terms of decreased workload for the ED physicians, increased patient satisfaction and decreased waiting times, SENs appear to be a useful solution to the problem of ED crowding. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
20. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.
- Author
-
Terhaar Sive Droste, Jochim S, van Turenhout, Sietze T, Oort, Frank A, van der Hulst, René Wm, Steeman, Vincent A, Coblijn, Usha, van der Eem, Lisette, Duijkers, Ruud, Bouman, Anneke A, Meijer, Gerrit A, Depla, Annekatrien Ctm, Scholten, Pieter, Loffeld, Ruud Jlf, Coupé, Veerle Mh, Mulder, Chris Jj, van der Hulst, René W M, Depla, Annekatrien C T M, Loffeld, Ruud J L F, Coupé, Veerle M H, and Mulder, Chris J J
- Abstract
Background: Given the increasing burden on colonoscopy capacity, it has been suggested that faecal immunochemical test (FIT) results could guide surveillance colonoscopy intervals. Against this background, we have evaluated the test accuracy of single and double FIT sampling to detect colorectal cancer (CRC) and/or advanced adenomas in an asymptomatic colonoscopy-controlled high-risk population.Methods: Cohort study of asymptomatic high-risk patients (personal history of adenomas/CRC or family history of CRC), who provided one or two FITs before elective colonoscopy. Test accuracy of FIT for detection of CRC and advanced adenomas was determined (cut-off level 50 ng/ml).Results: 1,041 patients provided a FIT (516 personal history of adenomas, 172 personal history of CRC and 353 family history of CRC). Five CRCs (0.5%) and 101 advanced adenomas (9.7%) were detected by colonoscopy. Single FIT sampling resulted in a sensitivity, specificity, PPV and NPV for CRC of 80%, 89%, 3% and 99.9%, respectively, and for advanced adenoma of 28%, 91%, 24% and 92%, respectively. Double FIT sampling did not result in a significantly higher sensitivity for advanced neoplasia. Simulation of multiple screening rounds indicated that sensitivity of FIT for advanced adenoma could reach 81% after 5 screening rounds.Conclusions: In once-only FIT sampling before surveillance colonoscopy, 70% of advanced neoplasia were missed. A simulation approach indicates that multiple screening rounds may be more promising in detecting advanced neoplasia and could potentially alleviate endoscopic burden. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
21. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study.
- Author
-
Oort FA, van Turenhout ST, Coupé VM, van der Hulst RW, Wesdorp EI, Terhaar sive Droste JS, Larbi IB, Kanis SL, van Hengel E, Bouman AA, Meijer GA, and Mulder CJ
- Subjects
- Adenoma pathology, Adult, Aged, Aged, 80 and over, Cohort Studies, Colorectal Neoplasms pathology, Feces chemistry, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Sensitivity and Specificity, Young Adult, Adenoma diagnosis, Colonoscopy, Colorectal Neoplasms diagnosis, Early Detection of Cancer, Immunologic Tests
- Abstract
Background: A single sampled faecal immunochemical test (FIT) has moderate sensitivity for colorectal cancer and advanced adenomas. Repeated FIT sampling could improve test sensitivity. The aim of the present study is to determine whether any of three different strategies of double FIT sampling has a better combination of sensitivity and specificity than single FIT sampling., Methods: Test performance of single FIT sampling in subjects scheduled for colonoscopy was compared to double FIT sampling intra-individually. Test positivity of double FIT sampling was evaluated in three different ways: 1) "one of two FITs+" when at least one out of two measurements exceeded the cut-off value, 2) "two of two FITs+" when both measurements exceeded the cut-off value, 3) "mean of two FITs+" when the geometric mean of two FITs exceeded the cut-off value. Receiver operator curves were calculated and sensitivity of single and the three strategies of double FIT sampling were compared at a fixed level of specificity., Results: In 124 of 1096 subjects, screen relevant neoplasia (SRN) were found (i.e. early stage CRC or advanced adenomas). At any cut-off, "two of two FITs+" resulted in the lowest and "one of two FITs+" in the highest sensitivity for SRN (range 35-44% and 42%-54% respectively). ROC's of double FIT sampling were similar to single FIT sampling. At specificities of 85/90/95%, sensitivity of any double FIT sampling strategy did not differ significantly from single FIT (p-values 0.07-1)., Conclusion: At any cut off, "one of two FITs+" is the most sensitive double FIT sampling strategy. However, at a given specificity level, sensitivity of any double FIT sampling strategy for SRN is comparable to single FIT sampling at a different cut-off value. None of the double FIT strategies has a superior combination of sensitivity and specificity over single FIT., (© 2011 Oort et al; licensee BioMed Central Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
22. Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study.
- Author
-
Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupé VM, Craanen ME, Meijer GA, Morsink LM, Visser O, van Wanrooij RL, and Mulder CJ
- Subjects
- Adult, Aged, Aged, 80 and over, Colorectal Neoplasms mortality, Female, Humans, Male, Middle Aged, Neoplasm Staging, Netherlands epidemiology, Prognosis, Prospective Studies, Surveys and Questionnaires, Survival Rate, Time Factors, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Delayed Diagnosis
- Abstract
Background: Diagnosing colorectal cancer (CRC) at an early stage improves survival. To what extent any delay affects outcome once patients are symptomatic is still unclear.Our objectives were to evaluate the association between diagnostic delay and survival in symptomatic patients with early stage CRC and late stage CRC., Methods: Prospective population-based observational study evaluating daily clinical practice in Northern Holland. Diagnostic delay was determined through questionnaire-interviews. Dukes' stage was classified into two groups: early stage (Dukes A or B) and late stage (Dukes C or D) cancer. Patients were followed up for 3.5 years after diagnosis., Results: In total, 272 patients were available for analysis. Early stage CRC was present in 136 patients while 136 patients had late stage CRC. The mean total diagnostic delay (SE) was 31 (1.5) weeks in all CRC patients. No significant difference was observed in the mean total diagnostic delay in early versus late stage CRC (p = 0.27).In early stage CRC, no difference in survival was observed between patients with total diagnostic delay shorter and longer than the median (Kaplan-Meier, log-rank p = 0.93).In late stage CRC, patients with a diagnostic delay shorter than the median had a shorter survival than patients with a diagnostic delay longer than the median (log-rank p = 0.01). In the multivariate Cox regression model with survival as dependent variable and median delay, age, open access endoscopy, number and type of symptoms as independent variables, the odd's ratio for survival in patients with long delay (>median) versus short delay (=median) was 1.8 (95% confidence interval (CI) 1.1 to 3.0; p = 0.01). Tumor-site was not associated with patient survival. When separating late stage CRC in Dukes C and Dukes D tumors, a shorter delay was associated with a shorter survival in Dukes D tumors only and not in Dukes C tumors., Conclusion: In symptomatic CRC patients, a longer diagnostic and therapeutic delay in routine clinical practice was not associated with an adverse effect on survival. The time to CRC diagnosis and initiation of treatment did not differ between early stage and late stage colorectal cancer.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.